Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 27:12:743979.
doi: 10.3389/fphar.2021.743979. eCollection 2021.

Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States

Jigang Chen  1   2 , Xin Tong  1   2 , Mingyang Han  3 , Songfeng Zhao  3 , Linjin Ji  4 , Yongkai Qin  3 , Zilong He  3 , Yuesong Pan  5   6 , Chunhui Wang  7 , Aihua Liu  1   2   6
Affiliations

Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States

Jigang Chen et al. Front Pharmacol. .

Abstract

Background: Glioblastoma multiforme (GBM) is a fatal type of brain tumor with a high incidence among elderly people. Temozolomide (TMZ) has proven to be an effective chemotherapeutic agent with significant survival benefits. This study aimed to evaluate the economic outcomes of radiotherapy (RT) and TMZ for the treatment of newly diagnosed GBM in elderly people in the United States (US) and China. Methods: A partitioned survival model was constructed for RT plus TMZ and RT alone among patients with methylated and unmethylated tumor status. Base case calculations and one-way and probabilistic sensitivity analyses were performed. Life-years, quality-adjusted life-years (QALYs), costs (in 2021 US dollars [$] and Chinese Yuan Renminbi [¥]), and incremental cost-effectiveness ratios (ICERs) were calculated. Results: RT plus TMZ was found to be associated with significantly higher costs and QALYs in all groups. Only US patients with methylated status receiving RT plus TMZ had an ICER ($89358.51) less than the willingness-to-pay (WTP) threshold of $100000 per QALY gained when compared with receiving RT alone. When the WTP threshold ranged from $100000 to $150000 from the US perspective, the probability of RT plus TMZ being cost-effective increased from 80.5 to 99.8%. The cost of TMZ must be lower than ¥120 per 20 mg for RT plus TMZ to be cost-effective among patients with methylated tumor status in China. Conclusion: RT plus TMZ was not cost-effective in China, and a reduction in the TMZ price was justified. However, it is highly likely to be cost-effective for patients with methylated tumor status in the US.

Keywords: cost-effective; glioblastoma multiforme; radiotherapy; temozolomide; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Model structure of a decision tree combining the partitioned survival model GBM: glioblastoma; OS: overall survival; PFS: progression-free survival; RT: radiotherapy; TMZ: temozolomide.
FIGURE 2
FIGURE 2
One-way sensitivity analyses from the Chinese perspective. AE: adverse event; EV: expected value; MRI: magnetic resonance imaging; PD: progressive disease; PFS: progression-free survival; RT: radiotherapy; TMZ: temozolomide.
FIGURE 3
FIGURE 3
One-way sensitivity analyses from the US perspective. AE: adverse event; EV: expected value; MRI: magnetic resonance imaging; PD: progressive disease; PFS: progression-free survival; RT: radiotherapy; TMZ: temozolomide.
FIGURE 4
FIGURE 4
Cost-effectiveness acceptability curves. RT: radiotherapy; TMZ: temozolomide.
See this image and copyright information in PMC

References

    1. Baio G. (2020). survHE : Survival Analysis for Health Economic Evaluation and Cost-Effectiveness Modeling. J. Stat. Softw. 95 (14). 10.18637/jss.v095.i14 - DOI
    1. Commission on Macroeconomics and Health of World Health Organization Choosing Interventions that Are Cost Effective (WHO‐CHOICE). Available at: http://www.who.int/choice/costs/CER_thresholds/en/ 2012. (accessed October 17, 2012).
    1. Connock M., Auguste P., Dussart C., Guyotat J., Armoiry X. (2019). Cost-effectiveness of Tumor-Treating fields Added to Maintenance Temozolomide in Patients with Glioblastoma: an Updated Evaluation Using a Partitioned Survival Model. J. Neurooncol. 143 (3), 605–611. 10.1007/s11060-019-03197-w - DOI - PubMed
    1. Davis F. G., Smith T. R., Gittleman H. R., Ostrom Q. T., Kruchko C., Barnholtz-Sloan J. S. (2020). Glioblastoma Incidence Rate Trends in Canada and the United States Compared with England, 1995-2015. Neuro Oncol. 22 (2), 301–302. 10.1093/neuonc/noz203 - DOI - PMC - PubMed
    1. Dolecek T. A., Propp J. M., Stroup N. E., Kruchko C. (2012). CBTRUS Statistical Report: Primary Brain and central Nervous System Tumors Diagnosed in the United States in 2005-2009. Neuro Oncol. 14 (5), v1–49. 10.1093/neuonc/nos218 - DOI - PMC - PubMed

LinkOut - more resources